Prognostic Factors in Aplastic Anemia Associated with HIV: A Review

Article · September 2024

CITATIONS
0

READS
10

2 authors:

Emmanuel Ifeanyi Obeagu
Africa University
2,100 PUBLICATIONS **36,090** CITATIONS
SEE PROFILE

Callistus Adewale Akinleye
Osun State University
111 PUBLICATIONS **588** CITATIONS
SEE PROFILE

Elite Journal of Medical Sciences. Volume 2 issue 9 (2024), Pp.73-84

https://epjournals.com/journals/EJMS

Prognostic Factors in Aplastic Anemia Associated with HIV: A Review

*Emmanuel Ifeanyi Obeagu[1] and Callistus Adewale Akinleye[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda.

[2]Department of Community Medicine, Osun State University, Osogbo, Nigeria

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Aplastic anemia (AA) is a severe hematologic condition characterized by the bone marrow's failure to produce adequate blood cells, leading to life-threatening complications such as infections, bleeding, and severe anemia. When associated with HIV, the prognosis of AA becomes particularly complex due to the compounded effects of HIV-induced immunosuppression and bone marrow dysfunction. This review explores the key prognostic factors influencing outcomes in patients with HIV-associated AA, focusing on the severity of cytopenias, HIV viral load, CD4 count, response to antiretroviral therapy (ART), and the role of hematopoietic stem cell transplantation (HSCT). The severity of cytopenias at diagnosis, along with the HIV viral load and CD4 count, are crucial indicators of prognosis. Patients with severe pancytopenia, high viral load, and low CD4 count typically face poorer outcomes due to increased vulnerability to infections and bleeding. The effectiveness of ART in controlling HIV and partially restoring bone marrow function plays a significant role in improving survival rates. However, selecting ART regimens that minimize bone marrow suppression is essential to avoid exacerbating the condition.

Keywords: *Aplastic anemia, HIV, Prognostic factors, Bone marrow failure, Immunosuppression*

Introduction

Aplastic anemia (AA) is a rare but serious condition characterized by the failure of the bone marrow to produce sufficient numbers of blood cells, leading to pancytopenia. This hematologic disorder results in a marked decrease in the production of red blood cells, white blood cells, and platelets, causing patients to suffer from anemia, increased susceptibility to infections, and a heightened risk of bleeding. The etiology of AA can be diverse, with causes ranging from genetic predispositions and autoimmune disorders to environmental factors such as exposure to toxins and

certain medications. Among the various causes, viral infections have been recognized as significant contributors to the development of AA, with HIV being a particularly noteworthy example due to its profound effects on the immune system and hematopoiesis. HIV, the causative agent of acquired immunodeficiency syndrome (AIDS), has a well-documented impact on the hematopoietic system. The virus can directly infect bone marrow progenitor cells and stromal cells, leading to impaired blood cell production. Additionally, the chronic immune activation and inflammation driven by HIV can result in the autoimmune destruction of hematopoietic cells, further exacerbating bone marrow failure. The coexistence of AA in HIV-infected individuals presents a unique and challenging clinical scenario, where the prognosis is influenced by a complex interplay of factors related to both the underlying bone marrow disorder and the immunosuppressive effects of HIV.[1-6] The incidence of AA in HIV-positive patients is not entirely understood, but it is believed to be higher than in the general population, likely due to the combination of direct viral effects and the impact of antiretroviral therapy (ART). ART, while crucial for controlling HIV replication and improving immune function, can also contribute to bone marrow suppression, particularly in regimens that include nucleoside reverse transcriptase inhibitors (NRTIs) or other myelosuppressive agents. This dual impact of HIV and its treatment on the bone marrow complicates the management of AA in these patients, making the identification of prognostic factors vital for optimizing therapeutic strategies and improving outcomes. Prognostic factors play a crucial role in guiding the management of AA associated with HIV. In patients with this dual diagnosis, the severity of cytopenias at presentation is one of the most important prognostic indicators. Severe pancytopenia, which reflects extensive bone marrow failure, is associated with a higher risk of life-threatening complications such as infections and hemorrhage. This highlights the need for early and aggressive intervention to manage cytopenias and prevent adverse outcomes. Moreover, the stage of HIV infection, as reflected by viral load and CD4 count, also significantly influences prognosis. Patients with high viral loads and low CD4 counts typically have worse outcomes due to their increased susceptibility to opportunistic infections and poor immune recovery.[7-12]

The response to ART is another critical determinant of prognosis in HIV-associated AA. ART can lead to partial or complete recovery of bone marrow function in some patients by reducing viral load and improving immune function. However, the choice of ART regimen requires careful consideration to avoid exacerbating bone marrow suppression. Certain ART drugs, particularly those with known myelotoxic effects, may need to be avoided or substituted with less toxic alternatives. The timing of ART initiation is also crucial, as starting therapy too early or too late can impact the overall prognosis and the patient's ability to tolerate treatment. Hematopoietic stem cell transplantation (HSCT) is considered the definitive treatment for severe AA, offering the potential for long-term remission or cure. However, the success of HSCT in HIV-positive patients depends on several factors, including the availability of a suitable donor, the patient's overall health, and the ability to control HIV infection during and after the transplantation process. The immunosuppressive therapy required for HSCT must be carefully balanced with the need to maintain effective ART, as inadequate control of HIV can lead to graft rejection or increased mortality from opportunistic infections.[13-18] Age and comorbidities further complicate the prognosis of AA in HIV-positive patients. Older patients and those with additional health conditions, such as cardiovascular disease or chronic liver disease, often have a poorer prognosis

due to their reduced ability to tolerate aggressive treatments and their higher risk of complications. These factors necessitate a personalized approach to treatment, where therapeutic decisions are tailored to the individual patient's health status, disease severity, and specific prognostic factors.[19-20]

Pathophysiology of Aplastic Anemia in HIV

Aplastic anemia (AA) in the context of HIV infection is the result of a complex interplay of direct viral effects, immune dysregulation, and the impact of antiretroviral therapy (ART). The pathogenesis of AA in HIV-positive individuals involves multiple mechanisms that ultimately lead to bone marrow failure and pancytopenia, characterized by the reduction of red blood cells, white blood cells, and platelets. HIV can directly infect the bone marrow, targeting hematopoietic progenitor cells and stromal cells, which are essential for the production and support of blood cells. The virus's presence in the bone marrow disrupts the normal microenvironment necessary for hematopoiesis, leading to impaired proliferation and differentiation of progenitor cells. Additionally, HIV can induce apoptosis in these progenitor cells, further depleting the bone marrow's capacity to generate blood cells. This direct cytopathic effect of HIV on the bone marrow is one of the primary mechanisms leading to AA in infected individuals.[21-24]

HIV infection is associated with chronic immune activation and dysregulation, which can contribute to the development of AA through autoimmune mechanisms. The persistent activation of the immune system in response to HIV leads to the production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and interleukin-2 (IL-2). These cytokines can have toxic effects on hematopoietic stem cells and the bone marrow microenvironment, inhibiting hematopoiesis and promoting the destruction of blood cell precursors. Moreover, HIV-induced immune dysregulation can result in the development of autoantibodies against hematopoietic cells, leading to their immune-mediated destruction. This autoimmune response is similar to the mechanisms observed in idiopathic AA, where autoreactive T cells target and destroy bone marrow cells, exacerbating the bone marrow failure seen in HIV-associated AA. While ART is essential for controlling HIV replication and improving immune function, some antiretroviral drugs can contribute to bone marrow suppression, further complicating the pathophysiology of AA in HIV-positive patients. Nucleoside reverse transcriptase inhibitors (NRTIs), such as zidovudine (AZT), are known to have myelotoxic effects, which can impair the proliferation and differentiation of hematopoietic progenitor cells. Prolonged use of these drugs can lead to cumulative bone marrow toxicity, increasing the risk of developing AA in patients on long-term ART. Additionally, ART-induced mitochondrial toxicity can result in oxidative stress and damage to the bone marrow, further compromising its ability to produce blood cells. The choice of ART regimen and the duration of therapy are therefore critical factors in managing the risk of AA in HIV-infected individuals.[25-30]

HIV-positive individuals are at increased risk for opportunistic infections, many of which can directly or indirectly impact bone marrow function. Infections such as cytomegalovirus (CMV), parvovirus B19, and Epstein-Barr virus (EBV) are known to cause bone marrow suppression, either by directly infecting bone marrow cells or by triggering immune responses that damage the bone marrow. These infections can exacerbate the hematologic abnormalities seen in HIV-

associated AA, contributing to the severity of the condition. HIV infection can also lead to dysregulation of hematopoietic growth factors, such as erythropoietin, granulocyte colony-stimulating factor (G-CSF), and thrombopoietin, which are critical for the production and maturation of blood cells. The disruption of these growth factors' normal production or signaling pathways can result in insufficient stimulation of hematopoiesis, contributing to the development and progression of AA in HIV-infected patients.[21-25]

Prognostic Factors in Aplastic Anemia Associated with HIV

Aplastic anemia (AA) in the context of HIV infection presents a unique clinical challenge, as the interaction between HIV-related immunosuppression and bone marrow failure complicates the disease course and treatment. Several prognostic factors influence the outcomes in patients with HIV-associated AA, including the severity of cytopenias, HIV viral load, CD4 count, response to antiretroviral therapy (ART), the potential for hematopoietic stem cell transplantation (HSCT), age, and the presence of comorbidities. The degree of cytopenia at diagnosis is one of the most critical prognostic factors in HIV-associated AA. Patients with severe pancytopenia—characterized by critically low levels of red blood cells, white blood cells, and platelets—are at a higher risk for life-threatening complications such as severe infections, bleeding, and organ failure. The presence of severe anemia can lead to hypoxia, while neutropenia increases susceptibility to bacterial and fungal infections, and thrombocytopenia heightens the risk of hemorrhage. Early identification and aggressive management of these cytopenias are crucial for improving patient outcomes.[26-30]

The HIV viral load and CD4 count are pivotal in determining the prognosis of patients with AA. A high viral load signifies active viral replication and greater immune suppression, which can exacerbate bone marrow failure and reduce the likelihood of hematopoietic recovery. Conversely, a low CD4 count is indicative of severe immune compromise, increasing the risk of opportunistic infections and reducing the body's ability to respond to bone marrow-directed therapies. Patients with lower CD4 counts and higher viral loads generally have a worse prognosis due to the compounded effects of immune suppression and hematologic failure. The effectiveness of ART in controlling HIV infection is a significant prognostic factor in HIV-associated AA. ART can improve immune function, reduce viral load, and, in some cases, lead to partial or complete recovery of bone marrow function. However, the choice of ART regimen is critical, as certain antiretroviral drugs, particularly those with myelotoxic effects, can exacerbate bone marrow suppression. ART regimens that minimize bone marrow toxicity while effectively controlling HIV are associated with better outcomes. The timing of ART initiation also plays a role; initiating therapy at an appropriate stage of the disease can optimize bone marrow recovery and improve survival.[31-35] HSCT remains the only curative option for severe AA, including cases associated with HIV. However, its success depends on multiple factors, such as donor availability, the patient's age, overall health, and the ability to control HIV during the transplantation process. HIV-positive patients undergoing HSCT require careful management to balance immunosuppressive therapy with effective ART to prevent graft rejection and opportunistic infections. Successful HSCT in HIV-positive individuals has been reported, but outcomes are often dependent on stringent patient

selection and meticulous post-transplant care. Age is a well-known prognostic factor in AA, with younger patients generally having better outcomes due to their ability to tolerate aggressive treatments, such as immunosuppressive therapy and HSCT. In contrast, older patients, particularly those with comorbid conditions such as cardiovascular disease, diabetes, or chronic liver disease, often face poorer prognoses. These comorbidities can complicate treatment, increase the risk of complications, and reduce the likelihood of recovery from bone marrow failure. Comprehensive management that considers these comorbidities is essential for optimizing treatment outcomes.[36-40]

Opportunistic infections are a significant concern in patients with HIV-associated AA, as they can further weaken the already compromised immune system and complicate the management of AA. Infections such as cytomegalovirus (CMV) or Epstein-Barr virus (EBV) can cause additional bone marrow suppression or lead to graft-versus-host disease (GVHD) post-transplant. The presence of these infections at the time of diagnosis or during treatment is associated with worse outcomes, emphasizing the need for proactive infection control and prophylaxis in this patient population. Immunosuppressive therapy, often used in the treatment of AA, aims to suppress the immune system's attack on the bone marrow. The response to IST in HIV-positive patients can be unpredictable, with some patients achieving remission while others may not respond adequately. Factors influencing the response to IST include the severity of AA, the degree of immune dysregulation, and the patient's overall immune status. Successful response to IST is associated with improved prognosis, but in the context of HIV, the risks of further immunosuppression and opportunistic infections must be carefully balanced. The role of supportive care in managing HIV-associated AA cannot be overstated. Regular monitoring of blood counts, aggressive management of infections, and timely blood transfusions are critical components of care that directly influence patient outcomes. Additionally, the use of growth factors, such as erythropoietin and granulocyte colony-stimulating factor (G-CSF), may support hematopoiesis and improve quality of life, though their use must be carefully monitored to avoid exacerbating underlying conditions.[41-50]

Management Strategies

Managing aplastic anemia (AA) in patients with HIV is a complex process that requires a multidisciplinary approach, balancing the treatment of HIV, the hematologic disorder, and any associated complications. The primary goals of management are to restore bone marrow function, control HIV replication, prevent and treat infections, and address any drug-related toxicities. The following outlines key management strategies for this challenging condition. The cornerstone of managing HIV-associated AA is the effective control of HIV through ART. However, the choice of ART regimen must be carefully considered to minimize myelotoxicity. Nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine (AZT) are known to cause bone marrow suppression and should be avoided in patients with AA. Instead, regimens that are less likely to affect bone marrow function, such as integrase strand transfer inhibitors (INSTIs) combined with non-myelosuppressive NRTIs, should be preferred. Regular monitoring of blood counts is essential to detect any adverse effects of ART on hematopoiesis, and adjustments should be made as necessary to optimize the balance between controlling HIV and preserving bone marrow function.[51-55] For patients with severe AA, immunosuppressive therapy (IST) is often necessary to

reduce immune-mediated destruction of bone marrow cells. The standard IST regimen typically includes antithymocyte globulin (ATG) combined with cyclosporine. This combination can suppress the immune system's attack on the bone marrow, potentially leading to hematologic recovery. However, in HIV-positive patients, the use of IST requires careful consideration due to the increased risk of opportunistic infections. Prophylactic antimicrobials and close monitoring are crucial to managing the risk of infections during IST. Additionally, the timing of IST in relation to ART initiation should be strategically planned to optimize outcomes. HSCT offers a potential cure for AA, including cases associated with HIV. However, it is a complex and high-risk procedure, particularly in HIV-positive patients who may have a compromised immune system. Successful HSCT in these patients requires careful patient selection, considering factors such as age, overall health, HIV viral load, and CD4 count. The patient's HIV must be well-controlled with ART before and after the transplant to reduce the risk of complications. Post-transplant care involves managing the risk of graft-versus-host disease (GVHD), monitoring for infections, and maintaining effective ART. HSCT should be considered in younger patients or those with severe AA who have not responded to IST.[56-65]

Supportive care is critical in managing HIV-associated AA, particularly in stabilizing the patient while more definitive treatments are pursued. This includes regular transfusions of red blood cells and platelets to manage anemia and thrombocytopenia, respectively. The use of hematopoietic growth factors, such as erythropoietin and granulocyte colony-stimulating factor (G-CSF), can stimulate the production of blood cells and reduce the need for transfusions. However, their use must be balanced with the potential risks, particularly in the context of HIV. Aggressive infection control measures, including prophylactic antimicrobials and prompt treatment of any infections, are also essential components of supportive care. HIV-positive patients with AA are at increased risk for opportunistic infections due to both their underlying immunosuppression and the immunosuppressive effects of AA and its treatments. Infection prevention is paramount and includes the use of prophylactic antibiotics, antivirals, and antifungals. Vaccination against common pathogens, such as Streptococcus pneumoniae and influenza, should be administered as appropriate, although live vaccines are generally avoided in immunocompromised patients. Prompt identification and treatment of infections are critical to prevent severe complications and improve outcomes in this vulnerable population.[66-74]

Regular monitoring of blood counts, viral load, CD4 count, and overall health status is essential in managing HIV-associated AA. Frequent assessments allow for the timely detection of complications, such as worsening cytopenias, drug toxicities, or opportunistic infections, and enable adjustments to therapy as needed. In patients receiving IST or HSCT, close monitoring for signs of infection, GVHD, and hematologic response is crucial. ART regimens may need to be adjusted based on the patient's hematologic response and tolerance, with a focus on maintaining viral suppression without exacerbating bone marrow suppression. Nutritional support is an often-overlooked aspect of managing patients with HIV-associated AA. Malnutrition can exacerbate the effects of AA and impair immune function, making nutritional assessment and support a key component of comprehensive care. Patients may benefit from dietary interventions to ensure adequate intake of essential nutrients, particularly those that support hematopoiesis, such as iron, folic acid, and vitamin B12. Additionally, rehabilitation services, including physical therapy and

counseling, can help improve the patient's quality of life and functional status during and after treatment.[75-82] The psychological impact of living with both HIV and AA can be profound, contributing to anxiety, depression, and reduced quality of life. Providing psychosocial support is an integral part of management, helping patients cope with the chronic nature of their illnesses and the demands of ongoing treatment. Counseling services, support groups, and mental health care should be made available to patients and their families. Addressing the psychosocial aspects of care can improve adherence to treatment, enhance patient well-being, and ultimately lead to better clinical outcomes.[83-87]

Conclusion

Aplastic anemia (AA) associated with HIV presents a complex and challenging clinical scenario that requires a multifaceted approach to management. The interplay between HIV-induced immunosuppression and bone marrow failure complicates treatment strategies, making it essential to carefully balance the goals of restoring hematopoiesis, controlling HIV replication, and preventing opportunistic infections. Prognostic factors such as the severity of cytopenias, HIV viral load, CD4 count, response to antiretroviral therapy (ART), and potential for hematopoietic stem cell transplantation (HSCT) play critical roles in determining patient outcomes. Management strategies must be tailored to the individual, with an emphasis on optimizing ART regimens to reduce myelotoxicity, using immunosuppressive therapy judiciously, and considering HSCT in suitable candidates. Supportive care, including blood transfusions, infection prevention, and nutritional support, is essential for stabilizing patients and improving quality of life. Regular monitoring and timely adjustments to treatment, along with comprehensive psychosocial support, are vital in addressing the ongoing needs of patients with HIV-associated AA.

References

1. Furlong E, Carter T. Aplastic anaemia: Current concepts in diagnosis and management. Journal of paediatrics and child health. 2020;56(7):1023-1028.
2. Chichetto NE, Polanka BM, So-Armah KA, Sung M, Stewart JC, Koethe JR, Edelman EJ, Tindle HA, Freiberg MS. Contribution of behavioral health factors to non-AIDS-related comorbidities: an updated review. Current HIV/AIDS Reports. 2020; 17:354-372.
3. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV, 2024; 2(1): 65-78
4. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
5. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 46-58
6. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(1):21-31
7. Obeagu EI, GU Obeagu. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health, 2024; 2 (1): 8-22

8. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com. 2024;12(01).
9. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine, 2024;2(1): 35-46
10. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology, 2024; 2(1): 34-46
11. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV, 2024; 2(1): 1-15
12. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science, 2024; 2(1): 33-42
13. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology, 2024; 2(1): 47-64
14. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology, 2024; 2(1): 1-13
15. Felker-Kantor EA, Wallace ME, Madkour AS, Duncan DT, Andrinopoulos K, Theall K. HIV stigma, mental health, and alcohol use disorders among people living with HIV/AIDS in New Orleans. Journal of urban health. 2019; 96:878-888.
16. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Asian J Dental Health Sci 2024;4(1):38-44. Available from: http://ajdhs.com/index.php/journal/article/view/63
17. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV, 2024; 2(2): 1-17
18. Obeagu EI, Obeagu GU.Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health, 2024; 2 (1): 22-34
19. Skalski LM, Sikkema KJ, Heckman TG, Meade CS. Coping styles and illicit drug use in older adults with HIV/AIDS. Psychology of Addictive Behaviors. 2013;27(4):1050.
20. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine, 2024; 2(2):104-115
21. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS spread: impact of religious leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
22. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.
23. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-7.

24. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV infection and cardiovascular diseases: the obnoxious duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
25. Hill K, Kuo I, Shenoi SV, Desruisseaux MS, Springer SA. Integrated care models: HIV and substance use. Current HIV/AIDS Reports. 2023;20(5):286-295.
26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 33-45
27. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22
28. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian J Dental Health Sci [Internet]. 2023 Jun. 15 [cited 2024 Sep. 7];3(2):7-14. Available from: http://ajdhs.com/index.php/journal/article/view/39
29. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):9-19.
30. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30
31. Alum EU, Obeagu EI, Ugwu OP, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine. 2023 Oct 13;102(41):e35673.
32. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review, 2024; 2(1): 37-50
33. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
34. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
35. Goodwin M. Black markets: the supply and demand of body parts. Cambridge University Press; 2006.
36. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32
37. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41
38. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
39. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64

40. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda . Elite Journal of Medicine, 2024; 2(1): 1-16
41. Mandania EW. Haematological and Immunological Abnormalities in People Living With HIV: A Review. Journal of Medical and Biomedical Laboratory Sciences Research. 2024;4(1).
42. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36
43. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.
44. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV, 2024; 2(3): 14-26
45. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-117
46. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73
47. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59
48. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Applied Sciences (NIJBAS). 2023;3(3).
49. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58
50. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35
51. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57
52. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
53. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20-35
54. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15
55. American Psychiatric Association. Practice guideline for the treatment of patients with HIV/AIDS. American Psychiatric Pub; 2000.

56. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
57. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72
58. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
59. Sukumaran RK. Long-Term Follow-Up and Chronic Complications. Contemporary Bone Marrow Transplantation. 2021:641-665.
60. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
61. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
62. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
63. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
64. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
65. Lyimo RA, Stutterheim SE, Hospers HJ, de Glee T, van der Ven A, de Bruin M. Stigma, disclosure, coping, and medication adherence among people living with HIV/AIDS in Northern Tanzania. AIDS patient care and STDs. 2014;28(2):98-105.
66. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
67. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
68. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
69. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
70. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
71. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
72. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46

73. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
74. Banerjee N, Goodman ZT, McIntosh R, Ironson G. Cognition, coping, and psychological distress in HIV. AIDS and Behavior. 2022;26(4):1074-1083.
75. Grau LE, Griffiths-Kundishora A, Heimer R, Hutcheson M, Nunn A, Towey C, Stopka TJ. Barriers and facilitators of the HIV care continuum in Southern New England for people with drug or alcohol use and living with HIV/AIDS: perspectives of HIV surveillance experts and service providers. Addiction science & clinical practice. 2017; 12:1-4.
76. Yu Y, Luo D, Chen X, Huang Z, Wang M, Xiao S. Medication adherence to antiretroviral therapy among newly treated people living with HIV. BMC public health. 2018; 18:1-8.
77. Li H, Wu X, Shen J, Lou S. Perspective and experience of patients with aplastic anemia on medication adherence. Patient preference and adherence. 2023:2215-2225.
78. Beichler H, Grabovac I, Dorner TE. Integrated care as a model for interprofessional disease management and the benefits for people living with HIV/AIDS. International Journal of Environmental Research and Public Health. 2023;20(4):3374.
79. Rajabiun S, Tryon J, Feaster M, Pan A, McKeithan L, Fortu K, Cabral HJ, Borne D, Altice FL. The influence of housing status on the HIV continuum of care: results from a multisite study of patient navigation models to build a medical home for people living with HIV experiencing homelessness. American Journal of Public Health. 2018;108(S7):S539-45.
80. Dale SK, Safren SA. Striving towards empowerment and medication adherence (STEP-AD): a tailored cognitive behavioral treatment approach for black women living with HIV. Cognitive and Behavioral Practice. 2018;25(3):361-376.
81. Ngcobo S, Scheepers S, Mbatha N, Grobler E, Rossouw T. Roles, barriers, and recommendations for community health workers providing community-based HIV Care in Sub-Saharan Africa: a review. AIDS Patient Care and STDs. 2022;36(4):130-144.
82. Obeagu EI, Ogu RIO, Ngwoke AO. Psychosocial Impact of Aplastic Anemia Diagnosis in HIV Patients: A Narrative Review. Elite Journal of Public Health, 2024; 2 (7): 35-46
83. Obeagu EI, Akinleye CA. Stabilizing Hemoglobin Levels: A Vital Aspect of Blood Transfusions in HIV Management. *Elite Journal of Haematology, 2024; 2(9):* 1-8
84. Obeagu EI, Akinleye CA. Promoting Fertility: Blood Transfusions and Reproductive Health in HIV-Positive Individuals. *Elite Journal of Haematology, 2024; 2(9):* 9-16
85. Obeagu EI, Akinleye CA. Minimizing Treatment-Related Depression: Blood Transfusions and Mental Health Support in HIV Care. Elite Journal of Public Health, 2024; 2 (7): 16-24
86. Obeagu EI, Akinleye CA. Promoting Social Integration: Blood Transfusions and Improved Social Well-being in HIV Patients. Elite Journal of Public Health, 2024; 2 (7): 25-34
87. Obeagu EI, Akinleye CA. Optimizing Physical Endurance: Blood Transfusions in HIV and the Improvement of Exercise Capacity. Elite Journal of Medicine, 2024; 2(9): 1-9